12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Company News  |  Deals

Merrion, Novo Nordisk deal

The partners will use Merrion Gastrointestinal Permeation Enhancement Technology (GIPET) absorption-enhancing technology in a feasibility study to boost the oral bioavailability of an undisclosed Novo compound. Novo...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >